Most antibodies to factor VIII have recently been shown to react with discrete regions of the factor VIII light chain (within the C2 domain) and/or the factor VIII heavy chain (within the amino-terminal segment of the A2 domain). The mechanism by which these antibodies, usually designated "factor VIII inhibitors," interfere with factor VIII function has been examined by determining their effect on factor VIII binding to a phospholipid. Factor VIII-phosphatidylserine binding was prevented by all seven factor VIII inhibitors that had strong factor VIII light chain reactivity and reduced by two inhibitors with weak anti-light chain reactivity. None of four inhibitors with heavy chain reactivity prevented factor VIII-phosphatidylserine interaction, though a partial reduction (< 50%) was noted for the intact IgG preparations. However, when Fab' fragments were substituted, no detectable reduction in factor VIII-phosphatidylserine binding was noted for the anti-heavy chain inhibitors and complete inhibition was retained by the anti-light chain inhibitors. These data suggest that a subset of factor VIII inhibitors, those that bind to light chain determinants, inactivate factor VIII by preventing its effective interaction with phospholipid.
Introduction
One of the most serious complications in the treatment of hemophilia A patients is the development of antibodies that inactivate factor VIII. These "factor VIII inhibitors" arise as alloantibodies in 5-20% of patients with severe hemophilia A who have been treated with factor VIII concentrates (1) . Factor VIII inhibitors also rarely occur as autoantibodies in normal individuals, in patients with autoimmune disorders, and in postpartum women (2) .
Inhibitor antibodies are restricted in their light chain and heavy chain composition (3, 4) , and they do not form immunoprecipitates or fix complement (3) . Regions on the factor VIII protein with which many inhibitors react have recently been identified by immunoblotting experiments. Initial studies with thrombin cleavage fragments of factor VIII demonstrated that > 90% of inhibitors react with either or both the 44-kD (heavy chain) and -72-kD (light chain) fragments ( Fig. 1) (5) .1 Subsequent more detailed epitope mapping by deletion analysis ofrecombinant factor VIII protein fragments has suggested that light chain-specific inhibitors recognize an epitope in the carboxy-terminal 17.3-kD, the C2 domain, and that heavy chain-specific inhibitors react with the amino-terminal 18.3-kD segment of the A2 domain (6, 7) (Fig. 1) .
In addition to information about the factor VIII epitopes that inhibitors recognize, it is important to know how these antibodies inactivate factor VIII. Among the possible functional effects are inhibition of thrombin cleavage which is necessary for factor VIII activation (8) , blocking the interaction of factor VIII with either factor IXa or factor X, and interference with the binding of factor VIII to phospholipid.
We report here studies that examine the effect of factor VIII inhibitors on the interacton of factor VIII with phospholipid (9) (10) (11) (12) . As factor VIII light chain binds to phosphatidylserine (PS),2 but not to phosphatidylcholine or phosphatidylethanolamine (1 1), we examined the possibility that inhibitors that recognize light chain epitopes interfere with factor VIII binding to PS. This has been documented in data obtained for 13 heavy and light chain-specific inhibitors.
Methods
Materials. L-a-Phosphatidyl-L-serine (PS) prepared from bovine brain was purchased from Sigma Chemical Co. (St. Louis, MO). Antihuman factor VIII monoclonal antibody MABO38 was obtained from Chemicon International, Inc. (El Segundo, CA) and anti-human factor VIII monoclonal antibody C8 (13) from JR Scientific (Woodland, CA). Peroxidase-labeled goat antibody to mouse immunoglobulins, 2.2'-azino-di-(3-ethyl-benzthiazoline sulfonate) (ABTS), and hydrogen peroxide were purchased from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg, MD). Purified human factor VIII (2,000 U of factor VIII procoagulant activity [VIII:C]/mg) was a gift from Hyland Therapeutics (Glendale, CA). A freshly dissolved solution had 16 U/ml VIII:C, 13 U/ml factor VIII antigen (VIII:Ag), and 0.32 U/ml von Willebrand factor antigen (vWF:Ag).
Factor VIII measurements. VIII:C was measured by a one-stage method using factor VIII-deficient plasma as substrate (14>. VIII:Ag was measured by immunoradiometric assay using 125I-labeled Fab' prepared from the plasma of a patient (CC) with an alloantibody to factor VIII (15) . vWF:Ag was measured by immunoradiometric assay using a rabbit antibody (16 (17) . The inhibitor titer was determined by the Bethesda method (18) . Dr. Carol Fulcher kindly determined the epitope specificities ofthe inhibitors by immunoblotting with human factor VIII and thrombin cleaved factor VIII, as previously described (4, 5) . The factor VIII epitopes bound by the inhibitors and by the murine monoclonal antibody C8 were localized further by immunoblotting with the factor VIII protein deletion fragments described by Scandella et al. (7) . These fiagments were derived from a cDNA clone of factor VIII, and they were produced in Escherichia coli. The deletions removed contiguous segments of the 44-and 72-kD thrombin fragments. The epitope for MABO38 was determined by immunoblotting with human factor VIII and' thrombin-cleaved factor VIII ( 19) .
ELISA measurement of PS-bound factor VIII (PS-factor VIII).
The ELISA, a modification of the method described by Bloom (1 1 Factor VIII binding to phospholipid was determined by adding 100 Ml ofa monoclonal antibody to either the factor VIII heavy chain (C8) or the light chain (MABO38) ( Fig. 1 ) (1 MLg of IgG/ml in blocking buffer).
After a 2-h incubation at 371C, the wells were washed with washing buffer and peroxidase-conjugated anti-mouse immunoglobulin (0.2 Mg/ml in blocking buffer) was added to the wells. After a further 2-h incubation at 370C, the wells were washed and 100 Ml of ABTS solution containing 0.01% hydrogen peroxide was added. The absorbance at 405 nm was determined after a 15-min reaction at room temperature, and the factor VIII concentration was calculated from the average value for duplicate wells using a standard curve like that shown in Fig. 2. PS-factor VIII complex formation was blocked in a dosage-depenIdent manner by the addition of PS to the factor VIII in solution.
Inhibition of 50% was noted at a PS concentration of 0.3 Mg/ml.
Comparison offactor VIII inhibitor effects onfactor VIII:C activity and PS-factor VIII complexformation. Factor VIII in blocking buffer (1 U VIII:Ag/ml) was incubated for 2 h at 370C with an equal volume of inhibitor IgG diluted in blocking buffer. Residual VIII:C was then determined for one part of the mixture and a separate 0.1-ml aliquot was assessed by ELISA to determine if the factor VIII would bind to phospholipid. Factor VIII incubated with blocking buffer alone was the control for both VIII:C activity and PS-factor VIII complex formation assays. Each inhibitor was tested at least twice, once using serial half-log dilutions and once with serial twofold dilutions of inhibitor IgG. In every case, similar results were obtained in the two studies.
Control studies were carried out in which factor VIII was omitted from the mixture in order to be certain that the assay results were not due to anti-phospholipid antibodies. The 13-inhibitor IgG, tested at 100Mg/ml, had no reactivity with PS in these assays, i.e., they had the same low (0.06-0.14) absorbance at 405 nm as did normal IgG.
Protective effect ofPS on the immune inactivation of VIII:C activity. PS was homogenized and diluted to 30 MJml in barbital-buffered saline (15) . 0.1 ml ofeach PS solution was preincubated with 0.1 ml of factor VIII (2 U VIII:C/ml) at 370C for 20 min before 0.1 ml of inhibitor IgG was added. After 2 h of incubation at 370C, residual VIII:C was determined. In a separate set of mixtures, 0.1 ml of inhibitor IgG was incubated with factor VIII (2 U VIII:C/ml) at 370C for 2 h before the 0.1 ml ofPS solution was added. After an additional 20-min incubation at 370C, residual VIII:C was measured.
Results
Properties offactor VIII inhibitor antibodies. We studied 13 human factor VIII inhibitor antibodies in detail. Their characteristics are summarized in Table I . When examined by immunoblotting analysis, five of the inhibitors bound to factor (Fig.  1) . The amount of factor VIII bound, as measured by subsequent reactivity with anti-factor VIII (Fig. 2) , was. directly related to the amount of factor VIII added to the well. The effect of light chain inhibitors on the formation of PS-factor VIII complexes was initially measured with C8 and that of heavy chain inhibitors with MABO38 to avoid potential interference by the inhibitors on monoclonal antibody binding to the same chain. It was subsequently recognized that the two monoclonal antibodies gave similar data when used to detect factor VIII binding in the presence ofthe factor VIII inhibitors (Table II) .
The effect of inhibitors on PS-factor VIII complex formation depended on the inhibitor specificity. Typical values for a heavy chain-specific and a light chain-specific inhibitor are given in Table II . As increasing amounts of IgG were added, residual VIII:C activity fell to < 3% in both cases. However, the light chain inhibitor (MP) reduced PS-factor VIII binding to < 6 and 13% of that in control wells, while the heavy chain inhibitor (RM) IgG reduced binding by only 50 and 58%. Both VIII:C inactivation and the reduction in PS-factor VIII complex formation by anti-light chain IgG were progressive over the 2-h incubation. We tested 11 other inhibitors in the same way, and their effects on residual VIII:C activity and PS-factor VIII complex formation were determined (Fig. 3-5 ). IgG prepared from the four heavy chain-specific inhibitor plasmas inactivated al! VIII:C activity but had only a moderate effect on PS-factor VIII complex formation (50% or less) (Fig. 3 A) . In contrast, the five light chain-specific inhibitors (Fig. 4 A) inactivated VIII:C activity and PS-factor VIII complex formation to similarly low levels. Although two of the three type II anti-light chain inhibitors completely blocked PS-factor VIII complex formation, they did not completely inactivate VIII:C activity (17) .
We also examined four inhibitors that bound to both heavy and light chain determinants. As shown in Fig. 5 , two inhibitors, NS and EM, that reacted weakly with the light chain in immunoblotting experiments, had intermediate properties. IgG concentrations that completely inactivated factor VIII:C activity had an effect on PS-factor VIII complex formation between that of strictly light chain (Fig. 4) and heavy chain (Fig. 3) inhibitors. Inhibitors that reacted strongly with both heavy and light chain determinants (CC and WC) had properties like those of the light chain inhibitors. There was no (< 5%) inhibition of either VIII:C or PS-factor VIII complex formation by 0.1-10.0 mg/ml normal human IgG.
Although there was a consistent difference in the effect of light chain and heavy chain inhibitors on PS-factor VIII complex formation, the partial reduction by heavy chain-reactive IgG was unexpected. This was most likely due to a steric effect of the IgG-heavy chain interaction on PS-factor VIII complex formation in the test system. Fab' prepared from three heavy chain-reactive inhibitor IgGs had no (< 5%) effect on PS-factor VIII complex formation even though VIII:C inactivating properties were intact (Fig. 3 B) , while the properties of one the antibodies (20) (21) (22) (23) . Typical experiments are illustrated in Fig. 6 . IgG prepared from the plasma of a patient with an inhibitor that had light chain specificity (MP) was incubated with factor VIII in two different dilution series. When PS was preincubated with factor VIII, VIII:C inhibition was reduced from that of a mixture of inhibitor plus factor VIII incubated together before the PS was added. An 85% reduction in MP inhibitor activity (Bethesda units per microgram IgG) was noted when PS was incubated with factor VIII before the antibody was added (Fig. 6 A) . In contrast, the two dilution series gave nearly identical inactivation results if the IgG had antiheavy chain specificity (Fig. 6 B) .
Similar studies were carried out twice with each of the 13 inhibitors. Consistent results were obtained: a 74.5±7.5% re- Fab' (RC) were similar to the IgG from which it was prepared. In contrast, three of four Fab' prepared from light chain specific inhibitor IgG had VIII:C inactivating and PS-factor VIII complex inhibiting effects like the IgG from which they were prepared (Fig. 4 B) while one Fab' preparation (F) had only a modest effect on PS-factor VIII complex formation (40-60% reduction) when tested in concentrations that inactivated 83-88% of the VIII:C activity. Protective effect ofPS on VIII:C activity. Evidence of PSfactor VIII complex formation was also sought in experiments that determined the effect of PS on the VIII:C inactivation by duction in the inhibitor titer for the five anti light chain specificity when factor VIII was pr PS, 16.5±12.1% for the four antibodies with h( ficity, and 33.9±9.3% for the two antibodi strongly with both heavy chain and light cha (CC and WC, Table I ). These data indicate interacts with PS in a way that limits subseq with the factor VIII inhibitor.
Discussion
Our studies demonstrate a range of effects of hibitors on the binding of factor VIII to immc interaction was strongly inhibited by all sevei had light chain epitope specificity, but not by tors that had only heavy chain specificity. Twi weak reactivity for light chain epitopes, as well chain reactivity, had an intermediate effect.
Although anti-heavy chain factor VIII in affect PS-factor VIII complex formation to they inactivated factor VIII activity, a co (< 50%) effect on complex formation was not this as a steric effect of the IgG in this in vit: Fab' prepared from three inhibitor IgGs had n the assay (Fig. 3 B) . This is good evidence that factor VIII epitope remote from the PS-bindi (< 50%) effect of one of anti-heavy chain Fa that there is heterogeneity within the small heavy chain inhibitors tested. Data for the inhibitors demonstrate that Fab' can be as effet PS-factor VIII complex formation as the IgG prepared (Fig. 4 B) . The limited effect of one Fab' (F) suggests that this inhibitor reacts wi epitope that is close to the phospholipid-bindi is separate from the epitope to which the othei (Fig. 4 B) (23) that phospholipid prevents the binding of some inhibitors to factor VIII. We have confirmed these results (Fig. 6 A) and have demonstrated that the protective effect of phosphatidylserine is most marked for those inhibitors that bind factor VIII light chain determinants in immunoblotting studies (4, 5 (12) . The epitopes recognized by the light chain inhibitors have been previously localized within the factor VIII C2 domain (7) . Since PS-factor VIII interaction is prevented by these inhibitors, it is likely that the phospholipid-binding site is located within the C2 domain ofhuman factor VIII. However, in light of the generally consistent structural and functional homologies between the factor V and factor VIII (24) , further studies are needed to reconcile our observations with recent data for the interaction of bovine factor V with phospholipid vesicles (25, 26) . While it is clear that the carboxy-terminal (light chain) 74-kD polypeptide ofactivated bovine factor V binds to phospholipid vesicles (25) , the major phospholipid-binding site appears to be within the A3 domain (26) . These studies do not exclude the possibility of lipid binding by the C2 region as well, however, and the C domains of factor VIII and factor V have a 20% amino acid homology with the discoidins (6, 24) , lectins from Dictyostelium discoideum that have binding affinity to negatively charged lipids like PS (27) .
Confirmatory data for the hypothesis that anti-light chain inhibitors interfere with hemostasis by preventing factor VIIIphospholipid interactions may come in the future from studies ofdysfunctional factor VIII. Although a mutant form of factor VIII with defective phospholipid-binding properties has not been identified, our data suggest that mutations or a small deletion in the C2 domain could generate that kind of molecule. Few hemophilic plasmas have enough dysfunctional factor VIII protein to examine phospholipid-binding properties, however, and the analysis offactor VIII molecular pathology is at a very early stage (28) .
The studies reported here, as well as the recent report by Foster et al. (29) identifying a discrete binding region for an anti-factor VIII inhibitory alloantibody (threonine351-serine372), begin to clarify the mechanisms by which factor VIII inhibitors interfere with factor VIII procoagulant activity. These techniques may be helpful in localizing the ways in which other factor VIII inhibitors act. Identification of the inhibitor binding regions and their mechanism of action should also lead to a better understanding of factor VIII structure-function relationships. This information may in turn suggest new ways to approach the treatment of patients with factor VIII inhibitors (30) .
